Abstract 5887
Background
Tumour tissue from individual patients with colorectal cancer may be cultured in vitro as three-dimensional tumoroids that resembles the biological features in vivo including chemotherapy sensitivity and resistance. Tumoroid formation is well-established for resected tumour tissue, but there is a lack of detailed descriptions of cultivating tumoroids from liver biopsies. The purpose of this study was to compare metastasis, imaging, biopsy histology and tumoroid yield.
Methods
Patients exposed to all standard medical treatment for metastatic colorectal cancer were included within an ongoing phase II clinical trial (NCT03251612). Biopsies from liver were obtained with 16G needles and other localizations 18G. Microscopy was used to evaluate necrosis (present or not) and to quantify the fraction of vital carcinoma cells: 0 (0%), 1 (0-10%), 2 (10-50%) or 3 (50-100%). Tumoroid formation was quantified as 0 (0 tumoroids), 1 (1-10), 2 (10-100), 3 (100-1000) or 4 (>1000). Biopsies of low quality were pooled up to three together for tumoroid formation. Elastography during ultrasound were used to measure the tissue stiffness of a subset of liver metastases and was together with metastasis size other explorative variables.
Results
A total of 78 biopsies from 27 biopsy sessions were included from liver (22), lung (2), carcinomatosis (1), muscle (1) or kidney (1). No serious adverse events related to biopsy procedures were observed. 37 (49%) of 76 biopsies for histology contained vital carcinoma cells and necrosis was present in 43 (57%). The number of tumoroids after cultivation correlated with the level of vital carcinoma cells in biopsies (p = 0.008) and trend-wise inversely with the stiffness of the tumour (p = 0.05) but not the size of metastasis (p = 0.97) nor presence of necrosis (0.98).
Conclusions
The tumoroid yield after cultivation of biopsies from chemo-refractory colorectal cancer patients correlates with the level of carcinoma cells determined by microscopy and probably with the stiffness of the metastasis. Necrosis and size of metastasis were not related. These findings may have great implications for selecting and evaluating biopsies for tumoroid formation in precision medicine to colorectal cancer patients.
Clinical trial identification
NCT03251612.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
2cureX.
Disclosure
L.H. Jensen: Research grant / Funding (institution): MSD; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): 2cureX. G. Hagel: Shareholder / Stockholder / Stock options, Full / Part-time employment: 2cureX. H. Harling: Advisory / Consultancy: 2cureX. O. Thastrup: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: 2cureX. All other authors have declared no conflicts of interest.
Resources from the same session
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract